Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several brokerages have recently commented on COLL. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a research note on Tuesday, February 10th.

Collegium Pharmaceutical Stock Down 3.0%

Shares of NASDAQ COLL opened at $33.78 on Friday. The firm’s fifty day moving average is $34.54 and its 200 day moving average is $41.58. Collegium Pharmaceutical has a 52 week low of $28.34 and a 52 week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company has a market cap of $1.10 billion, a price-to-earnings ratio of 16.56 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.49 EPS. On average, equities research analysts expect that Collegium Pharmaceutical will post 6.38 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the transaction, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president directly owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.85% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP boosted its position in Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after acquiring an additional 157,743 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after acquiring an additional 18,160 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after purchasing an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after purchasing an additional 3,891 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.